Vertex To Use Large Phase II Trial Population For Hep C Product

Vertex' 1,000-patient Phase II trials for VX-950 could inform "filing strategy," firm says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet